Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/4/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Anders Heijl

Wrong Dr. Anders Heijl?

Honorary Member

Company Description: The Glaucoma Research Society is a public interest, non-profit scientific association of outstanding glaucoma researchers that provides a forum to discuss and...   more

Employment History

  • Chairman of the Department of Ophthalmology
    Malmö University Hospital
  • Professor, Department of Ophthalmology
    Malmö University Hospital
  • Professor and Chairman, Department of Ophthalmology
    University of Lund , Sweden


  • M.D.
  • Ph.D.
  • MD
  • PhD
62 Total References
Web References
Members, 4 Jan 2015 [cached]
Dr. Anders Heijl
Dr. Anders Heijl, Sweden
Glaucoma Treatment, 27 Sept 2007 [cached]
These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."
Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said. Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.
Anders Heijl, MD, is ..., 1 Jan 2004 [cached]
Anders Heijl, MD, is Professor, Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden. He is the study director of the Early Manifest Glaucoma Trial, an inventor of STATPAC and GPA, and a consultant of Carl Zeiss Meditec, Inc. Dr. Heijl may be reached at +46 40 331000;
Like Dr. Quigley, Dr. Heijl emphasized the need for more individualized treatment plans.
"We need to tailor the patient's treatment much more to the individual than we used to do," he asserted. "The data from the modern trials show that interpatient variability is tremendously large. When a patient first comes to us and we don't have follow-up data, the initial treatment should be based on intraocular pressure plus risk factors other than intraocular pressure, but later it's very important to determine the patient's individual rate of progression."
Dr. Heijl stated that software such as the recently released Humphrey Glaucoma Progression Analysis (GPA) software (Carl Zeiss Meditec, Inc.) will start to play an important role in the management of glaucoma in the next 2 to 5 years. "GPA helps you decide if the eye is stable or if [the disease] is progressing, and, if it is progressing, [GPA software] shows how fast it is progressing," commented Dr. Heijl, who went on to explain that knowing the rate of progression enables the practitioner to make the treatment decisions most suitable to the stage of disease of a particular eye (Figure 1).
Dr. Heijl then pointed out that the GPA software is based on 10 years of experience from the Early Manifest Glaucoma Trial and has been adapted to SITA: "The nucleus of the new GPA is glaucoma change probability maps based on pattern deviations. He explained that the GPA software flags findings on a pointwise basis when they are reproducible and prints clear text messages of possible or likely progression. The software automatically eliminates unreliable fields, he said, "which here are fields with high numbers of false-positive answers. In addition, Dr. Heijl commented that the GPA software "automatically eliminates untrained first fields, if those are out of line with the following fields.
"Clinical assessment of glaucoma ..., 16 Oct 2010 [cached]
"Clinical assessment of glaucoma patients, or particularly patients who have suspect glaucoma, requires assessment of visual function test results and structural parameters comparing both diagnostic modalities in each eye," said Anders Heijl, MD, PhD, Professor and Chairman, Department of Ophthalmology, University of Lund, Sweden.
Members List, 4 Jan 2015 [cached]
Anders Heijl
Dr. Anders Heijl
Dr. Anders Heijl, Sweden
Other People with the name "Heijl":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.